✦ LIBER ✦

Determination ofin vitrodrug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma

✍ Scribed by S. Küpeli; M. Beksac; B. Küpeli; S. Baltaci; O. Süzer

Book ID: 110553441
Publisher: Springer Netherlands
Year: 1997
Tongue: English
Weight: 332 KB
Volume: 29
Category: Article
ISSN: 0301-1623
DOI: 10.1007/bf02551107

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitrodrug sensitivity testing of huma

In vitrodrug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b

✍ B. Küpell; S. Baltaci; M. Beksac; O. Süzer; S. Küpeli; O. Göĝüs 📂 Article 📅 1997 🏛 Springer Netherlands 🌐 English ⚖ 322 KB

In vitro sensitivity testing of human re

In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a

✍ de Riese, W. ;Allhoff, E. ;Stief, C. G. ;Lenis, G. ;Schlick, R. ;Liedke, S. ;Ant 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 602 KB

Samples of 38 human renal cell carcinomas (RCC) were subjected to routine histopathological examination but also to in vitro sensitivity testing with mitomycin C, vinblastine and interferon Alpha-2a at various concentrations corresponding to serum titers recommended to be effective in vivo, employin

Cytotoxic In vitro function in patients

Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2

✍ Cristina Feruglio; Renato Zambello; Livio Trentin; Pietro Bulian; Tiziano France 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Low serum alpha-fetoprotein level in pat

Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-fu and interferon-alpha-2b

✍ Yehuda Z. Patt; Richard Pazdur; Ruth Smith; Bernard Levin; Mark Roh; Boris Yoffe 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

Improved tolerability and quality of lif

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

✍ Nizar M. Tannir; Lorenzo Cohen; Xuemei Wang; Peter Thall; Paul F. Mathew; Eric J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views